Raymond Stoll, PhDCHIEF TOXICOLOGIST
Dr. Stoll was Potentia Pharmaceuticals’ Chief Toxicologist and took over the same duties when Apellis Pharmaceuticals was launched in 2010. Dr. Stoll started his career in drug development when serving in the United States Air Force while doing research in Endocrinology and Nephrology from 1968 through 1971 and supporting clinical trials investigating lipid lowering agents. In 1974 he was awarded a Ph.D. in Pharmacology and Toxicology from Purdue University; upon graduation he started his industrial career of over 35 years, initially at Merck in West Point, PA and then served as Manager, Associate Director and then Director of Preclinical Safety Assessment at Sandoz Pharmaceuticals, Inc.; Senior Director of Toxicology and Pathology at Cetus/Chiron; and Director of Toxicology and Safety Assessment at Boehringer Ingelheim Pharmaceuticals, Inc. He was awarded the title Highly Distinguished Scientist in Toxicology at BI. He is presently Adjunct Professor in Toxicology at University of Connecticut. He has served on numerous task forces in the PMA, and served as Chairperson of the DRUSAFE (Drug Safety) Steering Committee and was a working member of this subsection committee of the PMA for 25 years. Additionally, he served as PMA Safety Chairperson in ICH (International Conference on Harmonization) process I, II, and III from. He has authored over 35 scientific papers and numerous abstracts to date.
Dr. Stoll was responsible for the design, strategy, execution and toxicological regulatory issues of toxicology IND/NDA programs for 20 major pharmaceutical compounds approved for marketing by the FDA and European agencies. His scientific interests include toxicogenomics, carcinogenicity (secondary mechanisms of tumor induction), transgenic mice in carcinogenicity assessments, genotoxicology and computers/statistics used in preclinical toxicology testing.